|
Oncology Competitive Intelligence Leaders
Category: Conferences
AACR 2026: Beyond the Abstracts: Webinar
Executive Summary: ONCrg’s PhD analysts review the most significant early-stage oncology developments from AACR 2026 and preview key data expected at ASCO, covering cell therapies, antibody-drug conjugates (ADCs), immuno-oncology, and the DNA damage response (DDR) space.
AACR 2026: Beyond the Abstracts
Oncology Resource Group goes beyond the abstracts to discuss what really happened at AACR 2026.
Emerging Clinical Signals
Excerpt from Custom Post Type Indication: ECS
ASCO GU 2026 Analyst Briefing: Webinar
Executive Summary: ONCrg analyst Sarah Lockheed previews four late-breaking phase 3 readouts at ASCO GU 2026 covering the post-CPI RCC setting, adjuvant RCC, and perioperative and advanced bladder cancer — all centered on belzutifan combinations and the continued expansion of the enfortumab vedotin plus pembrolizumab franchise.
Pre-ASH 2025 Analyst Briefing: Webinar
Executive Summary: ONCrg analyst Patrick Nygren previews the highest-impact clinical presentations across hematologic malignancies at ASH 2025, covering CLL, multiple myeloma, NHL, and AML, with a focus on practice-changing phase 3 readouts and early-stage combination signals.
ESMO 25: Live Video Event, Analyst Briefing: ESMO – What to Watch in Breast Cancer
ONCrg breast cancer analyst Carla Cabrera, PhD reviews five potentially practice-changing phase 3 readouts from ESMO 2025, spanning early HER2-positive breast cancer, first-line triple-negative disease, and…